Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

The combination of Biothera's experimental drug Imprime PGG^® and Erbitux^® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13^th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

“We believe these results suggest a potential major advancement in the treatment of colorectal cancer. Extending life and eliminating the harmful side effects of chemotherapy would be a significant benefit to cancer patients. Further research is warranted by these results.”

"The results indicate that this combination is a potentially effective alternative to standard of care therapies that utilize chemotherapy," said Dan Conners, president of Biothera's Pharmaceutical Group. "We believe these results suggest a potential major advancement in the treatment of colorectal cancer. Extending life and eliminating the harmful side effects of chemotherapy would be a significant benefit to cancer patients. Further research is warranted by these results."

SOURCE Biothera, the Immune Health Company